Nasopharyngitis (Common Cold) - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 37

Nasopharyngitis (Common Cold) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Nasopharyngitis (Common Cold) - Pipeline Review, H1 2012', provides an overview of the Nasopharyngitis (Common Cold) therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngitis (Common Cold), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold). 'Nasopharyngitis (Common Cold) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nasopharyngitis (Common Cold).
- A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nasopharyngitis (Common Cold) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Nasopharyngitis (Common Cold) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Nasopharyngitis (Common Cold) Therapeutic Products under Development, Key Players in Nasopharyngitis (Common Cold) Therapeutics, Nasopharyngitis (Common Cold) Pipeline Overview, Nasopharyngitis (Common Cold) Pipeline, Nasopharyngitis (Common Cold) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nasopharyngitis (Common Cold) Overview
Therapeutics Development
An Overview of Pipeline Products for Nasopharyngitis (Common Cold)
Nasopharyngitis (Common Cold) Therapeutics under Development by Companies
Nasopharyngitis (Common Cold) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Nasopharyngitis (Common Cold) Therapeutics – Products under Development by Companies
Nasopharyngitis (Common Cold) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Nasopharyngitis (Common Cold) Therapeutics Development
SCOLR Pharma, Inc.
Hydra Biosciences, Inc.
Nasopharyngitis (Common Cold) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Phenylephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Resfenol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smart Textiles - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Camphor + Cineol + Menthol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Veldona - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRPM8 Antagonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zinc Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasopharyngitis (Common Cold) – Product Development Milestones
Featured News & Press Releases
Aug 26, 2011: Afexa Completes Interim Analysis On COLD-FX Pediatric Multi-Centre Clinical Trial
Oct 21, 2010: Afexa Launches Multi-Center Pediatric Clinical Trial On Cold/Flu Remedy Cold-FX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Nasopharyngitis (Common Cold), H1 2012
Products under Development for Nasopharyngitis (Common Cold) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
SCOLR Pharma, Inc., H1 2012
Hydra Biosciences, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012

List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H1 2012
Products under Development for Nasopharyngitis (Common Cold) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013
• Measles – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013